In murine models, treatment with VISTA antibodies increases the number of CD4 + and CD8 + tumor specific T cells in the TME and converts non-functional/exhausted CD8 + T cells to functional T cells [13, 14]. The gene discussed is CD4; the disease is neoplasm.